Connecting you with personalized support and resources     Dear John Doe, We’re glad you’ve chosen to continue receiving valuable support from Shared Solutions®. As you know, a strong support network is a great resource for helping you live your life to the fullest with relapsing-remitting multiple sclerosis (RRMS). Now we’d like to take it one step further We know that your interests, needs, and circumstances can change over time. In order for Shared Solutions® to better serve you, we’re asking that you fill out a short survey to help us identify the kinds of materials and services that are most important to you. What this survey can mean for you With the information you provide in this survey, Shared Solutions® can develop a program of support that is best suited to your needs and interests, wherever you are in your treatment experience. We can give you the right tools and strategies to help you stay on course with the therapy you trust—for the confidence to help you attain your treatment goals.   Let’s stay connected Please do not hesitate to call on Shared Solutions® at 1-800-887-8100. We can provide ways for you to stay current on RRMS and COPAXONE® (glatiramer acetate injection) developments, while supporting your needs every step of the way.                                     Please see Important Safety Information about COPAXONE® below. COPAXONE® (glatiramer acetate injection) is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. Important Safety Information about COPAXONE® • Do not take COPAXONE® if you are allergic to glatiramer acetate or mannitol   • Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again   • Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense   • A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes   • The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE®. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE®   You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. Please see full Prescribing Information. Your Shared Solutions® Team Privacy Policy |  Unsubscribe |  Terms of Use COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd. Shared Solutions® is a registered service mark of Teva Neuroscience, Inc. Teva Neuroscience, Inc., Copaxone Marketing, 11100 Nall Avenue, Overland Park, KS 66211 © 2013 Teva Neuroscience, Inc. COP-40705